Full Answer
Should you sell Pfizer stock now?
Pfizer Inc. ‘s prostrate cancer medicine Xtandi is in the crosshairs of a growing campaign for the government to seize patent rights to bolster competition. Sen. Elizabeth Warren (D-Mass.) and two other lawmakers are pushing the Biden administration to ...
Why buy Pfizer stock?
Pfizer Inc. (PFE) full year performance was 24.91% Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Pfizer Inc. shares are logging ...
Why to invest in Pfizer?
- Source the best science in the world
- Double our innovation success rate
- Bring medicines to the world faster
Can you buy Pfizer stock?
You can buy or sell Pfizer and other ETFs, options, and stocks. Pfizer Inc. is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide.
Should I buy or sell Pfizer stock right now?
19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last twelve months. There are currently 10 hold ratings and...
What is Pfizer's stock price forecast for 2022?
19 brokers have issued 12-month price targets for Pfizer's shares. Their forecasts range from $44.00 to $76.00. On average, they anticipate Pfizer'...
How has Pfizer's stock performed in 2022?
Pfizer's stock was trading at $59.05 on January 1st, 2022. Since then, PFE shares have decreased by 15.4% and is now trading at $49.97. View the b...
Are investors shorting Pfizer?
Pfizer saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 77,200,000 shares, an increase o...
When is Pfizer's next earnings date?
Pfizer is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022. View our earnings forecast for Pfizer .
How were Pfizer's earnings last quarter?
Pfizer Inc. (NYSE:PFE) announced its quarterly earnings results on Tuesday, May, 3rd. The biopharmaceutical company reported $1.62 EPS for the quar...
How often does Pfizer pay dividends? What is the dividend yield for Pfizer?
Pfizer declared a quarterly dividend on Thursday, April 28th. Investors of record on Friday, May 13th will be paid a dividend of $0.40 per share on...
Is Pfizer a good dividend stock?
Pfizer(NYSE:PFE) pays an annual dividend of $1.60 per share and currently has a dividend yield of 3.09%. Pfizer has been increasing its dividend fo...
What guidance has Pfizer issued on next quarter's earnings?
Pfizer issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of $6.25-$6.45 for the period, comp...
Is Pfizer stock pessimistic?
Moreover, Pfizer's projected growth rate is pessimistic.
Will Pfizer's earnings increase in 2025?
The company projects adjusted earnings will increase by a risk-adjusted compound annual growth rate in the double-digit percentages through the end of 2025. This growth is on top of Pfizer's juicy dividends that investors have loved for a long time.
Does Pfizer split profits?
Yes, Pfizer splits profits from the COVID-19 vaccine with its partner, BioNTech. But generating a level of earnings growth that should be enough, along with a sustained strong dividend, to enable the stock to double over the next five years isn't a difficult challenge for the big drugmaker.
What is Pfizer's biggest product?
Pfizer 's ( NYSE:PFE) biggest product right now is its coronavirus vaccine. The company and its partner BioNTech expect it to generate more than $33 billion this year. And Pfizer expects coronavirus vaccine revenue to account for 42% of its total revenue. The vaccine is definitely one good reason to buy shares of this big pharma player.
How long does it take for Pfizer to replace Eliquis?
Of course, generic competition eventually will erode sales of this blockbuster. But the court ruling gives Pfizer seven years to develop products that may replace Eliquis as a top revenue generator.
Who makes Eliquis blood thinner?
Eliquis, a blood thinner commercialized by Pfizer and partner Bristol Myers Squibb, won a very important decision in an appeals court. The court upheld an initial ruling protecting the blockbuster's patents -- including composition and formulation of the drug.
What other stocks do shareholders of Pfizer own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Intel (INTC), Verizon Communications (VZ), AbbVie (ABBV), Walt Disney (DIS), Exxon Mobil (XOM), NVIDIA (NVDA) and JPMorgan Chase & Co. (JPM).
What is Pfizer's stock symbol?
Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."
What guidance has Pfizer issued on next quarter's earnings?
Pfizer issued an update on its FY 2022 earnings guidance on Tuesday, February, 22nd. The company provided earnings per share (EPS) guidance of $6.350-$6.550 for the period. The company issued revenue guidance of $98 billion-$102 billion.
What is Albert Bourla's approval rating as Pfizer's CEO?
358 employees have rated Pfizer CEO Albert Bourla on Glassdoor.com. Albert Bourla has an approval rating of 92% among Pfizer's employees. This puts Albert Bourla in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
How much of Pfizer is held by institutions?
64.99% of the stock of Pfizer is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
How long has Pfizer been increasing its dividend?
Pfizer has been increasing its dividend for 12 years.
What is the dividend payout ratio of Pfizer?
Pfizer does not yet have a strong track record of dividend growth. The dividend payout ratio of Pfizer is 70.27%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Pfizer will have a dividend payout ratio of 47.42% next year.
The pharma stock is moving in the opposite direction of the overall market
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
Key Points
Pfizer's shares fell as the overall market rose after a pullback in recent days related to omicron concerns.
What happened
Shares of Pfizer ( NYSE:PFE) were sinking 4.4% as of 11:18 a.m. ET on Tuesday. The big drugmaker didn't report any new developments. Today's decline appears to be a by-product of the overall market rising after a pullback in recent days due to concerns about the spread of the coronavirus omicron variant.
So what
The reality is that little has changed in the expectations about the impact of the omicron variant since Monday when Pfizer's shares rose while many stocks were dropping. As such, little has changed about Pfizer's prospects. Today's move is probably more noise than anything else.
Now what
Investors will definitely want to monitor how the efficacy of Pfizer's vaccine with a booster dose fares against the omicron variant. If the efficacy wanes, it could lead to new orders for the omicron-specific vaccine version that Pfizer and BioNTech are developing.
Why is Pfizer down?
Another reason Pfizer has been down is that they've had some clinical setbacks. They really had high hopes for breast cancer drug Ibrance, and early breast cancer setting, and had a couple of clinical studies that didn't pan out so well, and so that's been another negative impact on the stock.
Why is Pfizer weighing down?
One of the big reasons is that Pfizer has been just weighed down by their legacy drugs, Lyrica, other drugs that have lost patent exclusivity, and it's really just weighed on their revenue growth, earnings growth, and that's been a big problem.
